Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer.

@article{Dohnal2007PhaseIS,
  title={Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer.},
  author={Alexander Michael Dohnal and Volker Witt and Heino Huegel and Wolfgang Holter and Helmut Gadner and Thomas Felzmann},
  journal={Cytotherapy},
  year={2007},
  volume={9 8},
  pages={755-70}
}
BACKGROUND Cancer vaccines employing DC in their capacity as APC have been tolerated well and have shown some efficacy in clinical studies. IL-12, a cytokine critical for type 1 T-helper (Th1) lymphocyte and cytotoxic T-lymphocyte (CTL) differentiation, when released from a DC-based cancer vaccine, may support the generation of a cellular T-cell response. METHODS We applied tumor cell lysate plus keyhole limpet hemocyanin (KLH)-loaded and 48-h lipopolysaccharide (LPS) plus IFN-gamma… CONTINUE READING